Adial Pharmaceuticals, Inc. WT EXP 073123
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income raised on -$7,001,890 over the previous period. Total operating expenses were $6,887,947.

Profit Margin

Adial Pharmaceuticals, Inc. WT EXP 073123 (NASDAQ:ADILW): Profit margin
2015 0 -817.99K
2016 0 -420.2K
2017 0 -1.13M
2018 0 -11.63M
2019 0 -8.59M
2020 0 -10.86M
2021 0 -19.42M
2022 0 -12.73M
2023 0 -7.00M

ADILW Income Statement (2015 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015
Revenue
Revenue
000000000
Cost of revenue
56460.50K55.10K56456505650565
Gross profit
-564-60.50K-55.10K-564-5650-5650-565
Operating exp.
Research and development
1.26M4.17M8.39M5.85M3.96M368.45K182.10K146.14K322.10K
Selling and marketing
000000000
Total operating expenses
6.88M13.31M17.74M10.92M8.24M6.98M995.28K410.80K819.25K
Operating income
-6.88M-13.31M-19.28M-10.92M-8.24M-6.98M-995.28K-410.80K-819.25K
Other income (expenses), net
-113.94K585.20K-228.68K34.99K-346.52K-3.48M-144.17K101.26K
Income before tax
-7.00M-12.73M-19.51M-10.89M-8.59M-11.63M-1.13M-420.2K-817.99K
Income tax expense
0-502-94.07K-32.49K0-3.47M3679.64K1.26K
Net income
-7.00M-12.73M-19.42M-10.86M-8.59M-11.63M-1.13M-420.2K-817.99K
Earnings per share
Basic EPS
-5.44-317.81-26.12-21.79-21.8-61.1-5.2-2.2-4.28
Diluted EPS
-5.44-317.81-26.12-21.79-21.8-61.1-5.2-2.2-4.28
Data sourceData sourceData sourceData sourceData sourceData source